CD274 and colonic neoplasm: In a CT26 colon cancer mouse model, immunotherapy applied in combination with VISTA and PD-L1 ICIs contributed to tumor regression and led to long-term survival in the mouse model, demonstrating the rationale for targeting VISTA in cancer immunotherapy.